Inv(16)(p13q22)/t(16;16)(p13;q22) Gene Rearrangement Quantitative MRD Monitoring in UAE | 1000 AED | DHA Licensed

Executive Summary & Core Metrics

This Real-Time PCR (qPCR) test provides quantitative minimal residual disease (MRD) monitoring for AML patients with the inv(16)/t(16;16) rearrangement, achieving a detection sensitivity of 0.001% (1 leukemic cell in 100,000 normal cells). The assay is processed under ISO 9001:2015 accreditation at a DHA-licensed laboratory in Dubai Healthcare City.

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection, available daily 8 AM – 11 PM.
Turnaround Time: 4 Days from sample receipt; reports delivered Wednesday or Saturday.
Clinical Guidance: Telephonic post-test result interpretation included.
Insurance: Direct billing verification via WhatsApp +971 54 548 8731.

Test Overview & Methodology

This advanced Real-Time PCR (qPCR) assay monitors minimal residual disease (MRD) in acute myeloid leukemia (AML) patients carrying the inv(16)(p13q22)/t(16;16)(p13;q22) chromosomal rearrangement. It quantifies CBFB-MYH11 fusion transcripts with a sensitivity of 0.001%, enabling early detection of molecular relapse and guiding therapeutic decisions. The test adheres to international MRD monitoring standards and is performed at our DHA-licensed facility in Dubai Healthcare City.

Feature	Our Test (inv(16) MRD by qPCR)	Closest Alternative (Multiparametric Flow Cytometry)
Precision	0.001% leukemic cells (1 in 100,000)	0.01–0.1% leukemic cells (1 in 1,000–10,000)
Methodology	Real-Time PCR (qPCR) – ISO 9001:2015 Accredited	Multiparametric Flow Cytometry
Turnaround Time	4 Days (samples Mon/Thu by 11 am; reports Wed/Sat)	7–10 Days
Sample Requirement	Peripheral blood (10 mL EDTA) or bone marrow (2–3 mL)	Fresh bone marrow (3–5 mL in heparin)

Physician Insight & Safety Protocols

“Quantitative MRD monitoring by qPCR offers unparalleled sensitivity for detecting submicroscopic residual disease in AML patients with inv(16)/CBFB-MYH11 rearrangements. Serial measurements are essential to distinguish molecular remission from impending relapse. However, results must always be interpreted alongside full hematological parameters and clinical assessment. A single negative MRD result does not eliminate the possibility of disease recurrence.”

— Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403

Advisory: Medication & Treatment Continuity

Do not discontinue or modify prescribed chemotherapy, targeted therapy, or supportive medications without explicit instruction from your treating hematologist. MRD results inform treatment decisions—they do not replace clinical judgment.

Exclusion Criteria & Emergency Red Flags

Active infection or fever >38°C at time of sampling may compromise test integrity.
Severe thrombocytopenia (<10,000/µL) requires special precautions for bone marrow aspiration; our collection team will coordinate with your hematologist.
If you experience shortness of breath, uncontrolled bleeding, or new neurological symptoms, seek immediate emergency care before scheduling the test.

Note: Peripheral blood collection is preferred for routine MRD monitoring and can be performed via VIP Mobile Phlebotomy at home. Bone marrow aspiration requires a hospital procedure.

Patient FAQ & Clinical Guidance

1. What does this test measure and why is it critical for my AML care?

This Real-Time PCR assay quantifies CBFB-MYH11 fusion transcripts—the genetic hallmark of inv(16)/t(16;16) AML. MRD monitoring detects one leukemic cell among 100,000 normal cells, providing the earliest warning of molecular relapse. Rising MRD levels typically precede hematologic relapse by 2–6 months, allowing pre-emptive therapy adjustments. Serial MRD testing is now the standard of care for core-binding factor AML.

2. How should I prepare for sample collection?

No special preparation is required. For home collection via VIP Mobile Phlebotomy, our team will bring a complete cold-chain kit. You must provide a completed MRD Requisition Form including historical cytogenetic and molecular data. The sample must be refrigerated immediately after collection—never frozen. Our courier ensures temperature-controlled transport to our DHA-licensed laboratory within 2 hours.

3. What do my results mean and when will I receive them?

Results report the MRD percentage. A value below 0.001% indicates deep molecular response. A rising level above 0.1% suggests imminent relapse and warrants urgent hematology review. Reports are delivered within 4 days (samples collected Mon/Thu by 11 am; reports available Wed/Sat). A telephonic post-test consultation with our clinical genetics team is included for result interpretation.

4. Is this test covered by my health insurance?

We offer direct billing verification for most UAE insurance plans. Contact our billing team via WhatsApp at +971 54 548 8731 with your policy details to confirm coverage. Self-pay option is also available at 1,000 AED.

UAE Regulatory & Data Privacy Adherence

Our laboratory operates under the regulatory oversight of the Dubai Health Authority (DHA) and complies with:

Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) — governing the collection, processing, and storage of your health information.
Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields — ensuring secure digital handling of medical records and test results.
Federal Decree-Law No. 4 of 2016 on Medical Liability — establishing patient safety standards and clinical accountability for all diagnostic procedures.

Your test data is encrypted and accessed only by authorized medical personnel. You have the right to access, correct, or request deletion of your personal data per PDPL Article 13.

Clinical & Logistical Metadata

Test Name	Inv(16)(p13q22)/t(16;16)(p13;q22) Gene Rearrangement Quantitative MRD Monitoring
Price (AED)	1,000
Turnaround Time	4 Days (samples collected Mon/Thu by 11 am; reports Wed/Sat)
Sample Type / Matrix	Peripheral Blood (10 mL EDTA) or Bone Marrow (2–3 mL EDTA)
Methodology Used	Real-Time PCR (qPCR) – ISO 9001:2015 Accredited
ICD-10-CM Code	C92.0 (Acute myeloid leukemia with abnormal chromosomal clone)
LOINC Code	69125-5 (CBFB-MYH11 fusion transcript [Presence] in Blood or Bone Marrow by PCR)
DHA Facility License & Laboratory Address	License No: 1143 \| Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE \| Corporate Lab: DNA Labs UAE